

Charles Hugh-Jones, MD, FRCP

Global Chief Medical Officer

Member of the Management Board since: January 1, 2026

Appointed until: December 31, 2028

Personal data:

Born: 1969
Gender: Male
Nationality: British with U.S. citizenship
Education: Qualified in Medicine (MD),
Charing Cross and Westminster Medical School, London
Bachelor in Neuroanatomy (BSc),
Charing Cross and Westminster Medical School, London
Fellow, Royal College of Physicians, UK FRCP
Primary Fellowship, Royal College of Radiologists FRCR I
Member, Royal College of Physicians, UK MRCP

Professional experience:**Fresenius Medical Care AG**

2026 – present Global Chief Medical Officer and Member of the Management Board

Volastra Therapeutics

2020 – 2025 Chief Executive Officer

Allergan plc

2018 – 2020 Global Chief Medical Officer

Pfizer Inc.

2017 – 2018 Chief Medical Officer, Oncology Division

Sanofi Pharmaceuticals

2012 – 2016 Chief Medical Officer, North America Region

2011 – 2012 Head Medical, North America, Sanofi & Genzyme Oncology, Hematology &
Solid Organ Transplantation

2010 – 2011 Vice President, U.S. Medical Affairs, Sanofi Oncology

Enzon Biopharmaceuticals

2008 – 2010 Vice President, Chief Commercial Officer

2007 – 2008 Vice President, Head Medical Affairs

Schering AG / Berlex / Bayer (via mergers)

2005 – 2007 Executive Medical Director, Global Business Unit, Oncology

2003 – 2005 Medical Director, Global Business Unit, Hematology

2002 – 2002 Medical Advisor, Schering UK

National Health Service, UK1999 – 2002 Fellowship, Royal Postgraduate Teaching Hospital, Hammersmith
Hospital, London

1995 – 1999 Hospital Physician, Internship and Residency

Membership in supervisory boards or comparable supervisory bodies¹:

Board of Directors

Fresenius Medical Care Holdings, Inc., U.S.²

Board of Administration

Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland

¹ Non-executive Director. Unless stated otherwise, the companies are not public.

² Fresenius Medical Care Group mandate